CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
MAC27 - COMPASSHER2 residual disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and Tucatinib has closed to accrual.
The Ralph Meyer Phase III Program Young Investigator Award has been awarded to Dr. Rachel Glicksman from Princess Margaret Cancer Centre recognizing her active participation and enrollment activities as a young investigation in CCTG trials. This award is presented to individuals who have made significant contributions to the phase III program research projects.
It was an honour to recognize Judy Needham with the Excellence in Clinical Trials Conduct – Patient Engagement award for her unwavering commitment to patient engagement at CCTG. Judy joined CCTG as a Patient Representative in May 2012 on the Breast Site Committee and became the Chair, CCTG Patient Representatives Committee, in 2014, she successfully led the PRC for over 10 years stepping down this year.
Congratulations to Dr. Moira Rushton, a Medical Oncologist from the Ottawa Hospital Research Institute who has been awarded the Elizabeth Eisenhauer Early Drug Development Young Investigator Award for her work on CCTG IND trials and committees.
“I am truly honored to have been selected as the recipient of this year’s Elizabeth Eisenhauer early drug development young investigator award. My time at CCTG was an invaluable formative experience and continues to meaningfully impact my clinical practice and academic career,” says Dr Rushton.
Congratulations to the PR.24 trial team from Odette Cancer Centre who were presented the Phase III Program Team Award at the 2025 Spring Meeting for their work and dedication to this CCTG led prostate cancer trial. This recognition is awarded to a non-MD team of clinical research associates, nurses, pharmacists and others who participated in this phase III clinical trial to acknowledge their efforts and dedication to the success of clinical trials.
CCTG was pleased to present the Excellence in Clinical Trials Conduct award to Iryna Sokolenko at North York General Hospital for her work to support our trials and contributions to patient-focused research. Iryna is the PCRA for CRC.10 and has been recognized as having exceptional attention to detail who's genuine care made participating in the trial a positive experience for patients. This is presented annually to an individual who exemplifies excellence in clinical trial operations and compliance at their institution.
We are honoured to announce that the 2025 Joseph Pater Founder’s Award for Excellence in Clinical Trials Research has been presented to Dr. Rebecca Wong Princess Margaret Cancer Centre for her many years of trial and committee leadership with the group.She was Chair of CCTG’s Symptom Control (now Supportive Care) Committee from 2001-2018, and Esophageal disease-oriented group from 2009-2018. She is currently a member of CCTG’s Clinical Trials Committee.
